Sanofi (SNY) Long-Term Deferred Tax (2009 - 2026)

Sanofi has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $10.2 billion for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax rose 12.37% year-over-year to $10.2 billion; the TTM figure through Jun 2026 stood at $10.2 billion (up 12.37% YoY), while the FY2025 annual figure was $10.0 billion, up 16.2% from the prior year.
• Long-Term Deferred Tax came in at $10.2 billion for Q2 2026 at Sanofi, up from $10.0 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $10.2 billion in Q2 2026 to a low of $5.1 billion in Q2 2022.
• Average Long-Term Deferred Tax over 5 years is $7.7 billion, with a median of $7.8 billion recorded in 2024.
• Year-over-year, Long-Term Deferred Tax rose 0.23% in 2022 and grew 27.24% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $5.5 billion in 2022, then advanced by 25.96% to $6.9 billion in 2023, then rose by 23.12% to $8.5 billion in 2024, then grew by 17.7% to $10.0 billion in 2025, then gained by 1.65% to $10.2 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $10.2 billion in Q2 2026, $10.0 billion in Q4 2025, and $9.1 billion in Q2 2025.